阿夫凯泰改善梗阻性肥厚型心肌病患者健康状况:SEQUOIA-HCM研究结果
SEQUOIA-HCM 3期试验将282例有症状的梗阻性肥厚型心肌病患者随机分配至阿夫凯泰组(n=142)或安慰剂组(n=140)治疗24周,随后洗脱4周。结果显示,与安慰剂相比,阿夫凯泰显著改善KCCQ总体摘要评分(平均差7.9,95%CI 4.8-11.0,P<0.001)和SAQ7摘要评分(平均差7.8,95%CI 4.7-11.0,P<0.001),且获益在4周内出现;停药后阿夫凯泰组健康状况恶化更显著,进一步证实因果效应。
要点
- 阿夫凯泰治疗24周显著改善oHCM患者症状、功能和生活质量。
- KCCQ-OSS和SAQ7-SS平均差分别为7.9和7.8,均P<0.001。
- 停药后健康状况显著恶化,支持因果效应。
核心结论
- 在有症状的oHCM患者中,阿夫凯泰治疗24周显著改善健康状况,包括胸痛相关健康状况。
研究设计与样本
- SEQUOIA-HCM为3期随机对照试验,纳入有症状的oHCM成人,随机接受阿夫凯泰(n=142)或安慰剂(n=140)治疗24周,随后洗脱4周。
主要发现
- 阿夫凯泰组与安慰剂组24周KCCQ-OSS平均变化分别为13.3±16.3和6.1±12.6,平均差7.9(95%CI 4.8-11.0,P<0.001)。
- 阿夫凯泰组与安慰剂组24周SAQ7-SS平均变化分别为11.6±17.4和3.8±14.4,平均差7.8(95%CI 4.7-11.0,P<0.001)。
- 获益在4周内出现,且各亚组间无治疗效应异质性。
- 阿夫凯泰组 vs 安慰剂组达到KCCQ-OSS≥20分改善的比例为29.7% vs 12.4%,NNT为5.8;SAQ7-SS≥20分改善比例为31.2% vs 13.9%,NNT为5.8。
- 停药后阿夫凯泰组KCCQ-OSS恶化-16.2±19.0,安慰剂组-3.0±9.6(P<0.001);SAQ7-SS恶化-17.4±21.4 vs -2.5±13.3。
临床怎么用
- 对于有症状的oHCM患者,阿夫凯泰可考虑用于改善症状、功能和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients' health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been comprehensively described. OBJECTIVES: This study sought to determine the effect of aficamten on patient-reported health status, including symptoms of fatigue, shortness of breath, chest pain, physical and social limitations, and quality of life. METHODS: SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) randomized symptomatic adults with oHCM to 24 weeks of aficamten (n = 142) or placebo (n = 140), followed by a 4-week washout. The Kansas City Cardiomyopathy Questionnaire (KCCQ) and Seattle Angina Questionnaire 7-item (SAQ7) were serially administered. Changes in mean KCCQ-Overall Summary Score (KCCQ-OSS) and SAQ7-Summary Score (SAQ7-SS) from baseline to 24 weeks and following treatment withdrawal were compared using linear regression adjusted for baseline scores and randomization strata. Proportions of patients with clinically important changes were compared. RESULTS: Among 282 participants, the mean age was 59 ± 13 years, 115 (41%) were female, and 223 (79%) were White. Baseline KCCQ-OSS (69.3 ± 20.1 vs 67.3 ± 18.8) and SAQ7-SS (72.0 ± 21.0 vs 72.4 ± 18.3) were similar between aficamten and placebo groups. Treatment with aficamten, compared with placebo, improved both the mean KCCQ-OSS (13.3 ± 16.3 vs 6.1 ± 12.6; mean difference: 7.9; 95% CI: 4.8-11.0; P < 0.001) and SAQ7-SS (11.6 ± 17.4 vs 3.8 ± 14.4; mean difference: 7.8; 95% CI: 4.7-11.0; P < 0.001) at 24 weeks, with benefits emerging within 4 weeks. No heterogeneity in treatment effect was found across subgroups. A much larger proportion of participants experienced a very large health status improvement (≥20 points) with aficamten vs placebo (KCCQ-OSS: 29.7% vs 12.4%, number needed to treat: 5.8; SAQ7-SS: 31.2% vs 13.9%, number needed to treat: 5.8). Participants' health status worsened significantly more after withdrawal from aficamten than placebo (KCCQ-OSS: -16.2 ± 19.0 vs -3.0 ± 9.6; P < 0.001; SAQ7-SS: -17.4 ± 21.4 vs -2.5 ± 13.3), further confirming a causal effect of aficamten. CONCLUSIONS: In patients with symptomatic oHCM, treatment with aficamten resulted in markedly improved health status, including significant improvement in chest pain-related health status, than placebo. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818).
引用
- Sherrod CF, Saberi S, Nassif ME, et al. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024. PMID: 39217569. doi:10.1016/j.jacc.2024.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。